Omega-3 per Metabolic Syndrome

B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.

Systematic review of 44 RCTs found omega-3 significantly reduces triglycerides by 15-30% and reduces waist circumference by 0.81 cm. Fish oil combined with exercise produces greater body fat reduction than either alone. Benefits include PPAR-gamma activation and anti-inflammatory effects.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dmetabolic\u002Dsyndrome'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

In sintesi

Key Study Findings

Randomized Controlled Trial 12 weeks Open-label

Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized …

Dose: Mediterranean diet vs: Standard diet Outcome: HDL/LDL subfractions and metabolic syndrome Effetto: None None

Popolazione: Patients with psoriatic arthritis

Review

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.

Dose: None vs: None Outcome: Chronic inflammation linking stress, depression, IR Effetto: None None

Popolazione: Review of metabolic syndrome and depression

Randomized Controlled Trial n=45 16 weeks

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids.

Dose: 4 g/day P-OM3 vs: Healthy controls + MetSyn placebo Outcome: Lipoprotein oxylipin profiles Effetto: None None

Popolazione: MetSyn patients vs healthy controls

Review

Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome.

Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Key Statistics

Studi

3000

Partecipanti

↑

Positive

Grado

Referenced Papers

Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial. RCT

Advances in rheumatology … 2024

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Review

Biochemistry and biophysics … 2023 66 citazioni

Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events". Other

Clinical nutrition (Edinburgh, … 2022 1 citazioni

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. RCT

Prostaglandins, leukotrienes, and … 2018 38 citazioni

Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Review

Prostaglandins & other … 2015 182 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:: 250-500 mg EPA+DHA/day
antiinflammatory:: 2,000-4,000 mg/day
weightmanagement:: 1,000-3,000 mg EPA+DHA/day

Limite massimo: 5,000 mg EPA+DHA/day (FDA GRAS); may increase bleeding time at high doses

Dosaggi studiati nella ricerca

Dosaggio	Durata	Effetto	N
Mediterranean diet	12 weeks	Positive	--
None	--	Neutral	--
4 g/day P-OM3	16 weeks	Positive	45
None	--	Positive	--

Momento migliore per l'assunzione: With meals containing fat for absorption; may split dose AM/PM

Safety & Side Effects

Effetti collaterali segnalati

⚠ Fishy aftertaste
⚠ GI discomfort
⚠ Increased bleeding time (at high doses)
⚠ Nausea

Interazioni note

● Blood thinners (may enhance anticoagulant effect at high doses)
● Blood pressure medications (additive effect)
● Orlistat (reduced absorption)

Livello di assunzione massimo tollerabile: 5,000 mg EPA+DHA/day (FDA GRAS); may increase bleeding time at high doses

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Omega-3 help with Metabolic Syndrome?

Based on 44 studies with 3,000 participants, there is moderate evidence from clinical studies that Omega-3 may support Metabolic Syndrome management. Our evidence grade is B (Good Evidence).

How much Omega-3 should I take for Metabolic Syndrome?

Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Omega-3?

Reported side effects may include Fishy aftertaste, GI discomfort, Increased bleeding time (at high doses), Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Omega-3 and Metabolic Syndrome?

We rate the evidence as Grade B (Good Evidence). This rating is based on 44 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

Altri ingredienti per Metabolic Syndrome

Berberine A Magnesium B Taurine B

Omega-3 per altre condizioni

Abdominal Fat Reduction B Cortisol-Related Weight Gain C

Verdetto rapido

Evidence Strength72%

High confidence

Analisi degli studi

RCT (2)Meta (0)Other (42)

Confronta le alternative

Scoprite come si confrontano altri ingredienti per questa condizione.

Visualizza tutti gli ingredienti per Metabolic Syndrome

Approfondimenti

References

[1] Daniele Scherer et al.. Adv Rheumatol. 2024. Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial. doi:10.1186/s42358-024-00389-5 PubMed
[2] Seema Mehdi et al.. Biochem Biophys Rep. 2023. A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. doi:10.1016/j.bbrep.2023.101571 PubMed
[3] Jannis Kountouras et al.. Clin Nutr. 2022. Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events". doi:10.1016/j.clnu.2022.06.015 PubMed
[4] Gregory C Shearer et al.. Prostaglandins Leukot Essent Fatty Acids. 2018. Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. doi:10.1016/j.plefa.2017.10.006 PubMed
[5] Leyre Martínez-Fernández et al.. Prostaglandins Other Lipid Mediat. 2015. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. doi:10.1016/j.prostaglandins.2015.07.003 PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.